Are drugs discovered in the clinic or the laboratory

[1]  A. Sands,et al.  Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.

[2]  J Rees,et al.  Post-genome integrative biology: so that's what they call clinical science. , 2001, Clinical medicine.

[3]  R. Bond.  Is paradoxical pharmacology a strategy worth pursuing? , 2001, Trends in pharmacological sciences.

[4]  James Le Fanu,et al.  The Rise and Fall of Modern Medicine , 1999 .

[5]  J. Berman,et al.  The precancers: waiting for a classification1 , 2003 .

[6]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[7]  L. Hardy,et al.  The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. , 2004, Drug discovery today.

[8]  David F. Horrobin,et al.  Realism in drug discovery—could Cassandra be right? , 2001, Nature Biotechnology.

[9]  R. Bond.  Can intellectualism stifle scientific discovery? , 2002, Nature Reviews Drug Discovery.

[10]  Michael N Liebman,et al.  Biomedical informatics: the future for drug development. , 2002, Drug discovery today.

[11]  A. Sands,et al.  Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. , 2003, Current opinion in pharmacology.

[12]  V. Alabaster,et al.  The fall and rise of in vivo pharmacology. , 2002, Trends in pharmacological sciences.

[13]  Esther F. Schmid,et al.  Discovery, innovation and the cyclical nature of the pharmaceutical business. , 2002, Drug discovery today.

[14]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[15]  J. Lindon,et al.  'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  I. Wilson,et al.  Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.

[17]  Richard C Lewontin,et al.  It Ain't Necessarily So: The Dream of the Human Genome and Other Illusions , 2000 .

[18]  D F Horrobin,et al.  Innovation in the pharmaceutical industry , 2000, Journal of the Royal Society of Medicine.

[19]  Laura Helmuth.  In Sickness or in Health? , 2003, Science.

[20]  Y. Lazebnik.  Can a biologist fix a radio? -- Or, what I learned while studying apoptosis, (Cancer Cell. 2002 Sep;2(3):179-82). , 2002, Biochemistry. Biokhimiia.

[21]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[22]  G. Duyk.  Attrition and Translation , 2003, Science.

[23]  Bruce L. Booth,et al.  Quest for the best , 2003, Nature Reviews Drug Discovery.

[24]  Jules J. Berman,et al.  Classifying the precancers: A metadata approach , 2003, BMC Medical Informatics Decis. Mak..